Proteon Therapeutics Inc (NASDAQ:PRTO) has received an average rating of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $4.00.
A number of research analysts have commented on PRTO shares. Zacks Investment Research upgraded Proteon Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 4th. Robert W. Baird set a $3.00 target price on Proteon Therapeutics and gave the company a “hold” rating in a research note on Wednesday, March 14th. Finally, HC Wainwright set a $2.00 target price on Proteon Therapeutics and gave the company a “hold” rating in a research note on Friday, March 16th.
Shares of PRTO stock traded down $0.20 during midday trading on Friday, reaching $2.60. The company’s stock had a trading volume of 51,781 shares, compared to its average volume of 43,053. Proteon Therapeutics has a 1 year low of $1.10 and a 1 year high of $2.85. The stock has a market capitalization of $49.49, a P/E ratio of -1.23 and a beta of 1.67.
Proteon Therapeutics (NASDAQ:PRTO) last issued its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.14. sell-side analysts forecast that Proteon Therapeutics will post -1.44 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Proteon Therapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Proteon Therapeutics Inc (NASDAQ:PRTO) by 17.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 201,500 shares of the biopharmaceutical company’s stock after acquiring an additional 29,600 shares during the quarter. Renaissance Technologies LLC owned about 1.14% of Proteon Therapeutics worth $383,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 50.56% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2018/03/24/proteon-therapeutics-inc-prto-given-average-recommendation-of-hold-by-brokerages.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.